Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2022 01/14/2022 01/18/2022 01/19/2022 01/20/2022 Date
148(c) 148.5(c) 139.19(c) 138.62(c) 138.33 Last
606 300 457 129 647 712 474 978 429 069 Volume
+0.31% +0.34% -6.27% -0.41% -0.21% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 821 M - -
Net income 2021 -760 M - -
Net cash position 2021 1 321 M - -
P/E ratio 2021 -21,5x
Yield 2021 -
Sales 2022 1 235 M - -
Net income 2022 -500 M - -
Net cash position 2022 1 323 M - -
P/E ratio 2022 -34,6x
Yield 2022 -
Capitalization 16 579 M 16 579 M -
EV / Sales 2021 18,6x
EV / Sales 2022 12,4x
Nbr of Employees 1 453
Free-Float 99,4%
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics are focused in four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and central nervous system/Ocular Diseases. The Company's RNAi-based medicines include... 
Sector
Biotechnology & Medical Research
Calendar
01/21 | 08:30amSpecial Situation
More about the company
Ratings of Alnylam Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALNYLAM PHARMACEUTICALS, INC.
07:50aHC Wainwright Boosts Price Target on Alnylam Pharmaceuticals to $350 From $250, Keeps B..
MT
01/18Morgan Stanley Adjusts Alnylam Pharmaceuticals' Price Target to $215 from $226, Keeps O..
MT
01/17Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
AQ
01/14Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
BU
01/14Alnylam Pharmaceuticals, Inc. to Present Full 18-Month Results from the HELIOS-A Phase ..
CI
01/10Alnylam Announces Preliminary Fourth Quarter and Full Year 2021 Global Net Product Reve..
AQ
01/10ALNYLAM PHARMACEUTICALS : Announces Preliminary* Fourth Quarter and Full Year 2021 Global ..
PU
01/10Alnylam Pharmaceuticals Reports Higher Preliminary 2021 Net Product Revenue
MT
01/09Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Rev..
BU
01/09Alnylam Pharmaceuticals, Inc. Announces Sales Results for the Fourth Quarter and Full Y..
CI
01/06Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Li..
BU
01/06Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Li..
CI
01/06Novartis, Alnylam Collaborate on Liver-Targeted Therapy
MT
01/06Novartis, Alnylam Pharmaceuticals Partner to Develop Liver-Targeted Therapy
MT
01/05ALNYLAM PHARMACEUTICALS : Announces Promotion of Dr. Akshay Vaishnaw to President - Form 8..
PU
More news
News in other languages on ALNYLAM PHARMACEUTICALS, INC.
01/14Alnylam Pharmaceuticals, Inc. présentera les résultats complets à 18 mois de l'étude de..
01/10Alnylam Pharmaceuticals annonce une hausse des recettes nettes des produits en 2021, se..
01/06Alnylam annonce une collaboration avec Novartis pour explorer une thérapie ciblée visan..
01/06Novartis und Alnylam forschen gemeinsam an Lebertherapie
01/06Novartis et Alnylam Pharmaceuticals s'associent pour développer une thérapie ciblant le..
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | ALNY | US02043Q1076 | MarketScreener
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 138,62 $
Average target price 211,33 $
Spread / Average Target 52,5%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet President, Chief Operating Officer & Director
Akshay K. Vaishnaw President-Research & Development
Jeffrey V. Poulton Executive VP, Chief Financial & Accounting Officer
Michael W. Bonney Independent Director
Pushkal Garg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-18.26%16 579
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
ICON PUBLIC LIMITED COMPANY-17.00%20 923